SciClone Pharmaceuticals Inc. (SCLN) Trading 2.3% Higher
SciClone Pharmaceuticals Inc. (NASDAQ:SCLN)’s share price traded up 2.3% during mid-day trading on Monday . The company traded as high as $10.93 and last traded at $10.80, with a volume of 226,962 shares traded. The stock had previously closed at $10.56.
The stock has a 50-day moving average price of $12.68 and a 200 day moving average price of $11.30. The company has a market cap of $543.01 million and a price-to-earnings ratio of 20.15.
SciClone Pharmaceuticals (NASDAQ:SCLN) last released its quarterly earnings data on Tuesday, May 10th. The specialty pharmaceutical company reported $0.19 earnings per share for the quarter. The company earned $36.50 million during the quarter, compared to the consensus estimate of $33.60 million. On average, equities analysts anticipate that SciClone Pharmaceuticals Inc. will post $0.33 earnings per share for the current fiscal year.
An institutional investor recently raised its position in SciClone Pharmaceuticals stock. Cornerstone Capital Management Holdings LLC. increased its stake in shares of SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) by 32.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 198,570 shares of the specialty pharmaceutical company’s stock after buying an additional 48,470 shares during the period. Cornerstone Capital Management Holdings LLC. owned approximately 0.40% of SciClone Pharmaceuticals worth $1,827,000 as of its most recent filing with the SEC.
SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.